CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
TIV +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03022435
NCT03022435Phase 4Completed
CompareCT.gov

Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 4, 2012

Stanford University·interventional·Posted Jan 16, 2017·Updated May 22, 2017

In Brief

A Phase 4 clinical trial evaluating TIV, High-Dose TIV, and 1 other intervention for Influenza. Completed, enrolled 22 participants.

Detailed Summary

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2017
Enrollment StartOct 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.5 years ago

Interventions

TIVbiological

Influenza Virus Vaccine Suspension for Intramuscular Injection

High-Dose TIVbiological

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe

LAIVbiological

Live, attenuated influenza vaccine for Intranasal Spray